Background The current ACR NI-RADS MRI lexicon does not include data about DWI. We hypothesised that incorporating DWI into the existing NI-RADS MRI descriptors could enhance its diagnostic performance. Methods This was a prospective study of 52 head-and-neck cancer patients who came for contrast-enhanced MRI surveillance 8-10 weeks after completing their curative treatment. Image analysis assessed the primary tumour site using the current ACR NI-RADS MRI morphologic criteria. Then, DWI was evaluated, and NI-RADS rescoring was performed based on qualitative DWI findings. An upgrade or downgrade of the existing NI-RADS categories was done, and diagnostic accuracy was calculated. Results Local tumour recurrence occurred in 30 patients (57.7%) while 22 patients (42.3%) had post-treatment changes. Final diagnosis was confirmed by histopathology in 26 patients (50%). Using morphologic data, 13 lesions were assigned the NI-RADS 1 category, 16 were assigned the NI-RADS 2, and 23 lesions were assigned the NI-RADS 3. When we added DWI data, eight NI-RADS 2 lesions were upgraded to NI-RADS 3, and seven of them were proven to be recurrent tumours. One NI-RADS 3 lesion was correctly downgraded to NI-RADS 2, which was proven on follow-up imaging to be post-treatment changes. Conclusions The combination of both morphologic ACR NI-RADS MRI criteria and DWI for primary tumour site assessment improves the overall diagnostic performance in predicting the presence of tumour recurrence.
No takes yet. Share an insight, caveat, or question.
Assem et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: